human menopausal gonadotropin
ApprovedSmall molecule
EMD Seronohuman menopausal gonadotropin is one of 79 small molecule programs targeting Hypogonadotropic Hypogonadism. It is currently in Approved.
3
Indications
11
Total Trials
0
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
175 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1Glucophage
Boehringer IngelheimPhase 3
Metformin XR
AstraZenecaPhase 3
human menopausal gonadotropin
EMD SeronoApproved
Oral Contraceptive Pills
SSheba Medical Center
Phase 3
Clomid
FerringPreclinical
Precose
BayerPreclinical
Proglycem
TevaPreclinical
Cetrotide
EMD SeronoPreclinical
Clomid
EMD SeronoPreclinical
Casodex
IIstituto Clinico Humanitas
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypogonadotropic Hypogonadism2 trials
Polycystic Ovary Syndrome1 trial
Pregnancy1 trial
Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders
Completed·—·N/A·NCT05103228·190 enrolled
Ovarian Reserve1 trial
Predictors of Ovarian Reserve in Infertile Women
Unknown status·—·Phase 4·NCT02896023·100 enrolled
5 more indications
Oocyte1 trial
The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles
Completed·—·Phase 4·NCT03209687·600 enrolled
Embryo1 trial
Ovarian1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company